The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Confirmation of the fantastic news.
https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-life-sciences-announces-grant-received-brigham-and
Tweet from Howard Weiner.
Received a grant to study nasal anti-CD3 in ALS. We found that nasal anti-CD3 treats models of ALS by dampening microglial activation. Although ALS is a motor neuron disease, microglial activation amplifies disease progression. If this works we will go directly to patients!
https://twitter.com/weinerlabhms/status/1570131546832793600?t=Vy2JVmVUd0Ugfs_xz1j1HA&s=19
Fantastic news that someone else is buying in. The first buy from someone else since 2020. Really encouraging.
Your thoughts have been passed on.
https://alzheimersnewstoday.com/news/foralumab-cd3-antibody-shows-promise-alzheimers-model/
I've been buying this week. As you say it looks like a bargain. No advice given if course.
400k shares. Bought them back just before the demerger of Accustem.
Keeren Shah:
Tiziana is a relatively small
biotech, but we are trying to do
something revolutionary in terms of
the administration of monoclonal
antibodies through nasal and oral
routes. This is our current pipeline,
but we’ve been through various
versions of our pipeline since the
company launched in 2014. It’s
interesting to hear from the other
panelists about being structured
in a silo and housing your IP in
different companies, because our
pipeline is constantly evolving.
Our spinout at Tiziana was based
around an asset—we were focused
on immunotherapies, and we had
an asset that was a diagnostic tool.
Tiziana had raised a substantial
amount of capital in 2020, and we
reviewed the pipeline and thought,
“Where can we add the value for
investors who have participated in
our various rounds of fundraising?
And how can we realize value
for this particular asset?” We
recognized that the company’s
management was structured to
focus on immunotherapies and
the platforms for delivery, but we
didn’t have people with expertise in
diagnostics. So that was the reason
for the spinout. At the time, Tiziana
was a listed company, so the way we
did the spinout for the shareholders
that had invested in the pipeline as a
whole was that we gave them mirror
holding in the new company based
on their holding in Tiziana. We felt
that this mirror register was the fairest
way to maximize value. The board
oversight is also identical between
the two companies. We also hired a
management team that was skilled
in this particular area. This was like
sending our ‘child’ into the big wide
world, so we also gave them financial
support to be able to succeed. Now
they have to raise the funds to take
this tool forward. We’ve had some
promising results; if we had retained
the tool within the company, I think
it would have been very difficult to
give it the focus and funding that it
deserved to make it a success
There has not been any mention about the great B Riley Call last week.!
All this chat about accustem is getting so boring on here now. It will happen when it happens. Yes it's taken far too long.
I think you need to learn how to read.. Shame you can't invest in specsavers.
I did not say that the MS dosing was a trial. I mentioned "program" which it is *factual*
I did not say that it was a success.. I mentioned "great results" *factual*
I am 100% not paid or encouraged by the company to share information or defend them.
You on the other hand.. I'm pretty certain are sang with your 2 day old profile, so are being added to my block list.
Can you message me on twitter shiraz.? Got some info for you.
The 57m was not to progress covid treatment. It was to fund the pipeline. They have said in numerous calls recently that the money will now last at least this year also.
So have we not proven to the FDA that the drug is suitable for use to dose patients in a wider trial. Have we not seen great results from the single patient dosing which has lead onto another patient being allowed to enter the program?
This is still early stages of a life sciences company. If you can't see that and appreciate the time that is needed for this to progress then you are in the wrong investment sector. Maybe some meme stock will be more suitable for you and the leech if you are not the same person anyway..!
Where did I say there was an official link from the company? The leech has already pointed out the link to the trial being cancelled.
It's logical that at this point it would be a waste of a huge amount of money to do a covid trial. Anyone truly invested in this must be able to see that it would be a waste of money at this point to start another trial in covid.
The covid trial was canceled because of the lack of need and its a business decision to not spend million of dollars on something that's not going to be in demand at this point in a Pandemic.
MS trial is going to the next due lift.
Or could be the $5 buy back first.
The rest of the information due from the company is trial starts or something left field that's not been published or due.